ClinicalTrials.Veeva

Menu

Statin Use in Abdominal Aortic Aneurysm Repair

U

University of Hull

Status and phase

Completed
Phase 4

Conditions

Abdominal Aortic Aneurysm

Treatments

Other: Placebo
Drug: Atorvastatin

Study type

Interventional

Funder types

Other

Identifiers

NCT01062802
CB/EL/R0135

Details and patient eligibility

About

Aneurysm formation is associated with a chronic inflammatory response, depletion of smooth muscle cell population and excessive matrix metalloproteinases (MMPs) production. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid lowering agents with pleiotropic effects including anti-inflammatory activity. Elective open AAA repair patients will be randomised to receive either statin (Atorvastatin 80 mg) or placebo (dummy tablet) for 4 weeks pre-operatively. Tissue samples will be obtained from patient's aneurysm to assess MMP's and their inhibitors TIMP's. It is hypothesized that patients receiving statin will have reduced MMP's.

Full description

All patients listed for elective open AAA repair will be screened for suitability to participate within the study. In this double blind randomized control trial patients will be recruited through vascular surgical outpatient clinics. After inclusion, informed consent and evaluation of base line characteristics patients will be given a prescription for study medication. This prescription was exchanged by the patient for medication at the hospital pharmacy. Randomization will be carried out by pharmacy with computer generated sequence with a sub group size of 4. This will ascertain the order of prescribed drug/ placebo. Pharmacy then dispensed the drug/ placebo in this order. Drug used will be Atorvastatin 80 mg, white, elliptical, film coated tablets debossed '80' on one side and 'PD 158' on the other side. The placebo is similar in shape and colour. Drug/ placebo will be given for 4 weeks pre-operatively. Full thickness infrarenal aortic samples will obtained at time of operation and the exact sample site will be recorded. Samples will be washed with 0.9% saline to remove blood and clots, snap-frozen and stored at -80C for subsequent MMP 2, 8 and 9 and TIMP 1 and 2 analyses.

Enrollment

40 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with an AAA >5.5cm diameter listed for open AAA repair at least 3 weeks from screening attendance.

Exclusion criteria

  • Patients already on statin,
  • inability to provide informed written consent,
  • contraindication to statin (intrinsic liver disease,
  • chronic alcohol abuse, impaired renal function, unstable hypothyroidism,
  • unexplained muscle aches, hypersensitivity to atorvastatin or any of its components),
  • previous unilateral or bilateral lower limb amputation and concomitant use of fibrates,
  • erythromycin,
  • immunosuppressive drugs,
  • antifungal drugs or lipid lowering drugs.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

40 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Treatment:
Other: Placebo
Statin group
Active Comparator group
Treatment:
Drug: Atorvastatin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems